Based on interim analysis of the now complete ADMIRAL trial (NCT02421939)11,12, gilteritinib was approved by the Food and Drug Administration (FDA) in November 2018 for treatment of adult patients with relapsed/refractory AML and a FLT3 mutation. Here, FLT3 is linked to acute myeloid leukemia.